Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Relutrigine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Praxis Precision Gets FDA Priority Review for Relutrigine in DEEs
    Praxis Precision Gets FDA Priority Review for Relutrigine in DEEs

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3264996/0/en/Praxis-Precision-Medicines-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-Relutrigine-in-Patients-with-SCN2A-and-SCN8A-DEEs.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    Praxis Precision Medicines Updates Corporate Progress
    Praxis Precision Medicines Updates Corporate Progress

    19 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/19/3240986/0/en/Praxis-Precision-Medicines-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    19 Feb 2026
    Share Share
    Praxis Precision Pharma Advances After A Key Year Of Achievements
    Praxis Precision Pharma Advances After A Key Year Of Achievements

    12 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/12/3216856/0/en/Praxis-Precision-Medicines-Enters-Its-Next-Chapter-Following-a-Pivotal-Year-of-Progress.html

    GLOBENEWSWIRE
    12 Jan 2026
    Share Share
    Praxis Precision Medicines To Submit NDA For Relutrigine
    Praxis Precision Medicines To Submit NDA For Relutrigine

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203828/0/en/Praxis-Precision-Medicines-Announces-Plans-to-File-an-NDA-for-Relutrigine-in-SCN2A-and-SCN8A-Developmental-and-Epileptic-Encephalopathies-in-Early-2026.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Praxis Leads in Rare Pediatric & Adult Epilepsies at AES
    Praxis Leads in Rare Pediatric & Adult Epilepsies at AES

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201478/0/en/Praxis-AES-Wrap-up-Best-in-Class-Potential-Across-Rare-Pediatric-and-Adult-Epilepsies.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    Praxis Precision Medicines Reports Positive EMBOLD Study Results
    Praxis Precision Medicines Reports Positive EMBOLD Study Results

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3200330/0/en/Praxis-Precision-Medicines-Announces-Positive-Results-from-EMBOLD-Study-for-Relutrigine-in-SCN2A-and-SCN8A-Developmental-and-Epileptic-Encephalopathies.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.